转化医学在原发性肝癌研究中的应用和展望

被引：5

作者：

邢昊

张汉

韩骏

沈艺南

沈锋

吴孟超

杨田

机构：

[1] 第二军医大学东方肝胆外科医院肝脏外科

来源：

中华实验外科杂志 | 2016年 / 33卷 / 10期

关键词：

原发性肝癌; 基础研究; 临床应用; 转化医学;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

原发性肝癌是一种全球性疾病,是世界第二大癌症相关死亡病因,全球范围内其发病率仍在上升。中国是肝癌大国,全世界55%的肝癌患者在中国,且中国的大多数肝癌患者在确诊时已处于晚期,失去了最佳治疗时机。原发性肝癌对大部分标准化疗方案不敏感,迄今为止被证实唯一有效的分子靶向药物仅有索拉菲尼。当前,原发性肝癌的基础研究集中于以下方面:(1)探索用于早期诊断的生物学标志物;(2)探求分子标志物与影像学、组织学特征的相关性;(3)鉴定新药物靶标和探索个体化疗法。本文主要探讨原发性肝癌基础研究领域的突破进展,对可能实现临床应用转化的研究进展进行综述。

引用

共 17 条

[1]

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial [J].

Zhu, Andrew X. ;

Park, Joon Oh ;

Ryoo, Baek-Yeol ;

Yen, Chia-Jui ;

Poon, Ronnie ;

Pastorelli, Davide ;

Blanc, Jean-Frederic ;

Chung, Hyun Cheol ;

Baron, Ari D. ;

Pfiffer, Tulio Eduardo Flesch ;

Okusaka, Takuji ;

Kubackova, Katerina ;

Trojan, Jorg ;

Sastre, Javier ;

Chau, Ian ;

Chang, Shao-Chun ;

Abada, Paolo B. ;

Yang, Ling ;

Schwartz, Jonathan D. ;

Kudo, Masatoshi .

LANCET ONCOLOGY, 2015, 16 (07) :859-870

[2]

The yin and yang of evasion and immune activation in HCC [J].

Makarova-Rusher, Oxana V. ;

Medina-Echeverz, Jose ;

Duffy, Austin G. ;

Greten, Tim F. .

JOURNAL OF HEPATOLOGY, 2015, 62 (06) :1420-1429

[3]

Making Sorafenib Irresistible: In Vivo Screening for Mechanisms of Therapy Resistance in Hepatocellular Carcinoma Hits on Mapk14 [J].

Avila, Matias A. ;

Berasain, Carmen .

HEPATOLOGY, 2015, 61 (05) :1755-1757

[4]

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Dikshit, Rajesh ;

Eser, Sultan ;

Mathers, Colin ;

Rebelo, Marise ;

Parkin, Donald Maxwell ;

Forman, David ;

Bray, Freddie .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386

[5]

Liver cancer biopsy – back to the future?!.[J].Michael Torbenson;Peter Schirmacher.Hepatology.2015, 2

[6]

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study [J].

Scartozzi, Mario ;

Faloppi, Luca ;

Baroni, Gianluca Svegliati ;

Loretelli, Cristian ;

Piscaglia, Fabio ;

Iavarone, Massimo ;

Toniutto, Pierluigi ;

Fava, Giammarco ;

De Minicis, Samuele ;

Mandolesi, Alessandra ;

Bianconi, Maristella ;

Giampieri, Riccardo ;

Granito, Alessandro ;

Facchetti, Floriana ;

Bitetto, Davide ;

Marinelli, Sara ;

Venerandi, Laura ;

Vavassori, Sara ;

Gemini, Stefano ;

D'Errico, Antonietta ;

Colombo, Massimo ;

Bolondi, Luigi ;

Bearzi, Italo ;

Benedetti, Antonio ;

Cascinu, Stefano .

INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (05) :1247-1256

[7]

Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT [J].

Yin, Lei ;

Li, Hui ;

Li, Ai-Jun ;

Lau, Wan Yee ;

Pan, Ze-ya ;

Lai, Eric C. H. ;

Wu, Meng-chao ;

Zhou, Wei-Ping .

JOURNAL OF HEPATOLOGY, 2014, 61 (01) :82-88

[8]

Epitope-Optimized Alpha-Fetoprotein Genetic Vaccines Prevent Carcinogen-Induced Murine Autochthonous Hepatocellular Carcinoma [J].

Hong, Yuan ;

Peng, Yibing ;

Guo, Z. Sheng ;

Guevara-Patino, Jose ;

Pang, Junfeng ;

Butterfield, Lisa H. ;

Mivechi, Nahid F. ;

Munn, David H. ;

Bartlett, David L. ;

He, Yukai .

HEPATOLOGY, 2014, 59 (04) :1448-1458

[9]

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.[J].Neeta K. Venepalli;Laura Goff;Pierluigi Toniutto.International Journal of Hepatology.2013,

[10]

Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2012.[J].M. Claudon;C. Dietrich;B. Choi;D. Cosgrove;M. Kudo;C. Nols?e;F. Piscaglia;S. Wilson;R. Barr;M. Chammas;N. Chaubal;M.-H. Chen;D. Clevert;J. Correas;H. Ding;F. Forsberg;J. Fowlkes;R. Gibson;B. Goldberg;N. Lassau;E. Leen;R. Mattrey;F. Moriyasu;L. Solbiati;H.-P. Weskott;H.-X. Xu.Ultraschall in Med.2013, 01

← 1 2 →